Clinical Trials Using Binimetinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Binimetinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-17 of 17
  • Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1189 locations

  • Binimetinib in Treating Younger Patients with Progressive or Recurrent Solid Tumors or Low-Grade Gliomas

    This phase I / II trial studies the side effects and best of dose binimetinib and to see how well it works in treating younger patients with solid tumors or low-grade gliomas that are growing, spreading, or getting worse (progressive) or have come back (recurrent). Binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 17 locations

  • Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)

    The purpose of this study is to determine safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) for the following combinations: pembrolizumab plus binimetinib (Cohort A), pembrolizumab plus mFOLFOX7 (oxaliplatin 85 mg / m^2; leucovorin [calcium folinate] 400 mg / m^2; fluorouracil [5-FU] 2400 mg / m^2) (Cohort B), pembrolizumab plus mFOLFOX7 and binimetinib (Cohort C), pembrolizumab plus FOLFIRI (irinotecan 180 mg / m^2; leucovorin [calcium folinate]400 mg / m^2; 5-FU 2400 mg / m^2 over 46-48 hours) (Cohort D), and pembrolizumab plus FOLFIRI and binimetinib (Cohort E).
    Location: 8 locations

  • A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

    This Phase 1b / 2 study will examine the effects of the study drugs, avelumab and binimetinib given together (doublet) and in combination with talazoparib (triplet), in patients with locally advanced or metastatic RAS-mutant solid tumors. The Phase 1b part of the study will assess if the different study drugs can be given together safely and which doses to use for further research. Phase 2 will test if the study treatments have an effect on tumor size and growth, and gather more information about potential side effects.
    Location: 4 locations

  • Binimetinib and Encorafenib in Treating Patients with Genetically Changed (Non-V600 Activating BRAF Mutant) Metastatic or Advanced Malignant Tumors

    This phase I / II trial studies the best dose and side effects of binimetinib and to see how well it works when given together with encorafenib in treating patients with malignant tumors that have spread to other places in the body and have a specific type of genetic mutation (non-V600 activating BRAF mutant). BRAF gene makes a protein that is involved in sending signals in cells and in cell growth. BRAF activating mutation may result in constant activation of cellular growth that may increase the growth and spread of cancer cells. Binimetinib and encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • encorAfenib, biNimetinib and Cetuximab in Subjects witH previOusly Untreated BRAF-mutant ColoRectal Cancer

    The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.
    Location: 4 locations

  • Palbociclib with or without Binimetinib or Binimetinib Alone in Treating Patients with Advanced KRAS Mutant Non-small Cell Lung Cancer

    This randomized phase I trial studies the side effects and best dose of palbociclib and binimetinib and to see how well they work in treating patients with KRAS mutant non-small cell lung cancer that has spread to other places in the body. Palbociclib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis

    This is a multicenter, randomized open-label Phase 2 study to assess the safety, efficacy and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in patients with BRAFV600-mutant melanoma with brain metastasis. Approximately 100 patients will be enrolled, including 9 patients in a Safety Lead-in of the high-dose treatment arm. After a Screening Period, treatment will be administered in 28-day cycles and will continue until disease progression, unacceptable toxicity, withdrawal of consent, start of subsequent anticancer therapy, death.
    Location: 2 locations

  • Pembrolizumab, Binimetinib, and Bevacizumab in Treating Participant with Metastatic Unresectable Colorectal Cancer

    This phase II trial studies how well pembrolizumab, binimetinib, and bevacizumab work in treating participants with colorectal cancer that has spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab, binimetinib, and bevacizumab may work better in treating participants with colorectal cancer.
    Location: University of Colorado Hospital, Aurora, Colorado

  • Combination Chemotherapy and Binimetinib in Treating Patients with KRAS Positive Metastatic Colorectal Cancer

    This phase Ib trial studies the side effects and best doses of combination chemotherapy when given together with binimetinib in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) positive colorectal cancer that has spread from the primary site (place where it started) to other places in the body (metastatic). Drugs used in chemotherapy, such as fluorouracil and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Binimetinib works in different ways to stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with binimetinib may kill more tumor cells.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Binimetinib and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumors

    This phase Ib / II trial studies the side effects and the best dose of binimetinib when given together with imatinib mesylate and to see how well they work in treating patients with untreated gastrointestinal stromal tumors that have spread from where they started to nearby tissue or lymph nodes or to other places in the body. Binimetinib and imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer

    This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who have received 1) first-line treatment with standard platinum-based chemotherapy, OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1) / programmed cell death protein ligand 1 (PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy will be enrolled.
    Location: 2 locations

  • Binimetinib in Combination with Docetaxel in Treating Patients with Previously Treated, Stage IV Non-small Cell Lung Cancer

    This phase Ib trial studies the safety and best dose of binimetinib when given in combination with docetaxel in treating patients with previously treated, stage IV non-small cell lung cancer. Binimetinib and docetaxel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Brigatinib and Binimetinib in Treating Patients with Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of brigatinib and binimetinib in treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Binimetinib and Palbociclib or TAS-102 in Treating Patients with KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

    This phase II trial studies how well binimetinib and palbociclib work compared to TAS-102 in treating patients with KRAS and NRAS mutation positive colorectal cancer that has spread to other places in the body or cannot be removed by surgery. Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving binimetinib and palbociclib may work better compared to TAS-102 alone in treating patients with colorectal cancer.
    Location: 8 locations

  • Avelumab with or without Binimetinib, Utomilumab, or anti-OX40 Antibody PF-04518600 in Treating Patients with Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

    This phase II trial studies how well avelumab alone compared to avelumab in combination with binimetinib, utomilumab, or anti-OX40 antibody PF-04518600 works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with monoclonal antibodies, such as avelumab, utomilumab, and anti-OX40 antibody PF-04518600 may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving avelumab in combination with binimetinib, utomilumab, or anti-OX40 antibody PF-04518600 will work better in treating patients with triple negative breast cancer compared to avelumab alone.
    Location: 4 locations

  • Pembrolizumab and Binimetinib in Treating Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer

    This phase I / II trial studies the best dose of pembrolizumab and binimetinib and how well it works when giving together with pembrolizumab in treating patients with triple negative breast cancer that has spread to other parts of the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and binimetinib may work better in treating patients with triple negative breast cancer.
    Location: 2 locations